The season finale puts you in the courtroom. The plaintiff's hematology expert says warfarin was the gold standard and the switch to rivaroxaban was unjustified. The defense experts say the evidence was unsettled and the decision fell within reasonable medical judgment. Same papers, opposite conclusions. We reconstruct both sides of the expert testimony, examine how courts handle gray-zone medicine, and close with practical lessons on documentation, shared decision-making, and what your chart note actually needs to say when you depart from the mainstream standard.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thecharteddefense.substack.com/subscribe